Johnson & Johnson Advances Nipocalimab in Lupus with Latest FDA Fast Track Nod

Johnson & Johnson announced that its investigational therapy nipocalimab has received U.S. FDA Fast Track designation for treating adults with systemic lupus erythematosus (SLE), a chronic autoimmune disease affecting 3 to 5 million people worldwide.

This marks the fifth Fast Track nod for nipocalimab, underscoring its potential to address unmet needs in autoantibody-driven conditions.

The FDA’s Fast Track program accelerates development and review for drugs targeting serious illnesses with few options, like SLE, which causes inflammation across organs such as the skin, joints, kidneys, blood, and central nervous system. Patients often endure severe fatigue, pain, swelling, rashes, and risks of irreversible damage from flares and steroid reliance.

“Nipocalimab earning its fifth FDA Fast Track designation, now in systemic lupus erythematosus, reflects the importance of accelerating the delivery of an immunoselective therapy that could fill an unmet need in this serious condition,” said Leonard L. Dragone, M.D., Ph.D., Disease Area Leader, Autoantibody and Rheumatology, Johnson & Johnson. “This is an important step in our efforts to help address the ongoing burden faced by people living with this debilitating disease.”

Positive Phase 2b Data Fuels Phase 3 Advancement

Building on positive results from the Phase 2b JASMINE study (NCT04882878), Johnson & Johnson has enrolled patients in the Phase 3 GARDENIA trial (NCT07438496) for active SLE. JASMINE, a 52-week, randomized, double-blind study in 228 adults, met its primary endpoint and key secondaries, including steroid-sparing potential. Nipocalimab stands as the first FcRn blocker to show reduced SLE disease activity.

“Systemic lupus erythematosus is a serious, complex disease that affects many aspects of a patient’s life, and treatment options remain limited,” said Richard Furie, M.D., Chief of Rheumatology at Northwell Health. “Progress like this brings renewed hope for more targeted therapies and meaningful outcomes.”

Understanding SLE and Nipocalimab’s Mechanism

SLE, the most common lupus form, strikes nine times more women than men, often between ages 15-44, impacting about 450,000 in the U.S. Symptoms like debilitating fatigue (affecting up to 80% of patients), joint pain, rashes (including the butterfly rash), and organ damage severely reduce quality of life.

Nipocalimab targets FcRn to selectively lower pathogenic IgG antibodies a root cause of SLE while preserving essential immune functions. It’s under investigation for rheumatologic, rare autoantibody, and maternal-fetal diseases.

Nipocalimab has earned an impressive array of regulatory designations across FDA and EMA programs, accelerating its path in autoantibody diseases. These include multiple FDA Fast Track, Orphan Drug, Breakthrough Therapy, and Priority Review statuses, plus EMA Orphan designations highlighting its potential in conditions like HDFN, gMG, FNAIT, and SjD.

These steps signal strong regulatory momentum for this immunoselective agent.

 Reference

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE), 03 March 2026, Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

A Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus, ClinicalTrials.gov ID NCT04882878, https://clinicaltrials.gov/study/NCT04882878

Johnson & Johnson Reports Positive Phase 2b JASMINE Trial Results for Nipocalimab in Systemic Lupus Erythematosus, 07 January 2026, https://pharmacally.com/johnson-johnson-reports-positive-phase-2b-jasmine-trial-results-for-nipocalimab-in-systemic-lupus-erythematosus/